

Index

- acetylcholine, and estrogen replacement therapy (ERT) 189–90
- adrenergic receptors, estrogen effects 253
- adrenocorticotrophic hormone (ACTH) 16
  - in aging, animal models 39–40
  - corticosterone regulation 305
  - dexamethasone/CRF test 43–4
  - HPA axis 16, 37–8, 292
- affect, estrogen 89
- affective disorders
  - therapy 63–6
  - thyroid hormones 63–4
- agoraphobia 242–3
- alcohol, and HPA 9
- alpha-1 acid glycoprotein, exogenous estrogen 325–6
- alprazolam 324
  - pharmacokinetics 337
- altanserin 98–9
- Alzheimer’s disease
  - apolipoprotein E as risk factor 174
  - $\beta$ -amyloid processing, estrogen effects 207
  - basal forebrain cholinergic neurons, summary of estrogen effects 203
  - cognitive function, DHEA and DHEA-S 152, 157
  - and estrogen 7–8
  - estrogen replacement therapy (ERT) 173–4
    - mechanisms of action 185–9
  - gender differences 322
  - HPA axis 43
  - loss of cholinergic neurons in MS and NBM 184–5
- amyotrophic lateral sclerosis 64
- analgesia
  - hypothalamic–pituitary–adrenal (HPA) axis 278
  - responses, sex differences 272–3
  - see also* stress-induced analgesia
- androgen receptors
  - CNS localization and subtypes 22–3
  - sexual dimorphism 25
- androgens
  - administration
  - depressed men 133–5
  - non-depressed eugonadal men 131–2
  - non-depressed hypogonadal men 133
- deficiency in aging males (ADAM) 8, 9
- in females 17
- HPH axis 323
- see also named substances*
- animal models
  - basal forebrain cholinergic neurons, memory deficit 185–9
  - estrogen replacement therapy (ERT), learning and memory 190–4
  - hypothalamic–pituitary–adrenal (HPA) axis 39–41
  - immune function, effects of estrogen(s) 290–6
  - ovulatory cycle, pain sensitivity 275
  - pain and pain inhibition 275–80
  - systemic lupus erythematosus 306
- anisomycin 147
- anorexia of aging, and hormones 10
- antibody production, effects of estrogen(s) 290
- anticonvulsants, pregnancy 327
- antidepressants
  - DHEA and DHEA-S 147–8
  - response to medication 149–50
  - and HPT axis 64–6
  - and thyrotrophin-releasing hormone (TRH) 61–2, 64–6
- antiestrogens, tissue-specific actions 104
- antipyrine, elimination, menstrual cycle 326
- antithyroid antibodies 59
  - depressed subjects 62
- anxiety disorders
  - avoidant personality disorder 248
  - causes 5
  - and female reproductive cycles 256–7
  - generalized anxiety disorder (GAD) 243–4
  - menopause 256–7
  - obsessive-compulsive disorder (OCD) 249–50
  - panic disorder 244–6
  - post-traumatic stress disorder (PTSD) 250–2
  - prevalence and type 241–2
  - and sex steroids 241–57
  - simple phobia 246–7

352 Index

- anxiety disorders (*cont.*)
    - social phobia 247–9
    - specific disorders, gender differences and aging effects 243–52
  - anxiolytics
    - DHEA and DHEA-S 147–8
    - response to medication 149–50
  - apolipoprotein E
    - and estrogen 174
    - risk factor for AD 174
  - arginine vasopressin (AVP) *see* vasopressin
  - astroglia, growth potential of DHEA and DHEA-S 148
  - atropine, cholinergic neurons, and memory dysfunction 184–5
  - autoimmune diseases, gender differences 306
  - $\beta$ -amyloid processing 207
  - basal forebrain cholinergic neurons 185–9
    - and cognition 183–211
    - estrogen effects 183–211
    - summary 203
  - benzodiazepines
    - binding to progesterone 341–6
    - elimination half-life 328
    - estrogen effects 204–6
    - and OCs 254–5, 326, 337–9
    - pharmacokinetics, influence of aging 336–9
  - brain injury, neuronal repair, potential of DHEA and DHEA-S 148
  - brain–hormone interactions, and behavior 11
  - brain-derived neurotrophic factor (BDNF)
    - estrogen effects, hippocampal formation 198–200
    - immobilization stress 40
  - breast tumors, cytochrome P450 (CYP 3A4) 324
  - c-erb 101
  - c-fos 309
  - c-jun 309
  - cardiovascular disease
    - estrogen(s)
      - and nitric oxide 100
      - protective action 103, 104
    - and psychotropic drugs 322
    - and stress responses 293–4
  - CD8+ cells, estrogen receptors 308
  - cell aging 309–11
  - chlorpromazine 328
  - cholecystokinin 10
  - cholesterol
    - HDL and LDL, estrogen effects 169
    - source for pregnenolone 6, 15, 17
    - steroid synthesis 15–18
  - choline, high affinity uptake (HACU) 186–90
  - choline acetyltransferase (ChAT) 168–9, 202
  - estrogen effects 186–9
- cholinergic neurons
    - estrogen effects, mechanisms 194
    - and memory dysfunction 184–5
  - circadian rhythms, HPA axis 39
  - clomipramine 327
  - clozapine 327
  - cognitive function
    - basal forebrain cholinergic neurons 184–5
    - combined laterality variable (CLV) 130
    - DHEA and DHEA-S 151–4
    - and estrogens 7–8, 168–9
    - non-demented women 169–72
    - gender differences 123–4
    - HPA axis 43–4
    - HPT axis 66–7
    - impairment, and dementia in the elderly 168–77
    - memory, DHEA administration 156–8
    - schizophrenia 226–7
    - and testosterone 174–7
    - Women’s Health Initiative Randomized Trial 176
  - cold, as stressor, thyroid hormone actions 26
  - coronary arteries and estrogen(s)
    - and nitric oxide 100
    - protective action 103, 104
  - corticotropin releasing factor (CRF, CRH) 9, 40–1, 289
    - Alzheimer’s disease 43
    - interactions with cytokines 41
    - interactions with estrogen(s) 296
  - cortisol 7
    - age-associated changes 42
    - binding 17
    - synthesis, inhibition by metyrapone 42
  - Cushing’s syndrome 44
  - cytochromes
    - 20,22-desmolase 15
    - P450
      - 2C19 324
      - CYP 1A1/2 325, 327
      - CYP 3A4 324, 327
      - estrogen metabolism 102
      - exogenous estrogen 325–6
      - metabolism 324
      - site of synthesis 18
    - P450<sub>17 $\alpha$</sub> , absence in brain 18
  - cytokines
    - interactions with corticotropin releasing factor (CRF) 41
    - levels, estrogen replacement therapy 291
    - levels and effects 5
  - dehydroepiandrosterone (DHEA and DHEA-S) 144–59
    - Alzheimer’s disease 152, 157

Cambridge University Press

0521653045 - Hormones, Gender and the Aging Brain: The Endocrine Basis of Geriatric Psychiatry

Edited by Mary F. Morrison

Index

[More information](#)**353****Index**

- antidepressant and anti-anxiety effects
  - animal models 147–8
  - responses 149–50
- cognitive function 151–4
- decline with age 5–6
- distribution 144–5
- general functional properties 150–1
- interindividual variability 145–6
- learning and memory, animal models 146–7
- levels
  - correlation with mood, memory and functional abilities 148–54
  - decrease with aging, chronic stress and illness 145–6
  - in females, systemic lupus erythematosus 306
  - mood disorders 148–9, 155–6
- as a neurosteroid 144
- neurotrophic potential 148
- treatment effects
  - general functioning 154–5
  - well-being, mood and memory 154–8
- deiodinases 54
  - generation of tri-iodothyronine (T<sub>3</sub>) 65–6
  - and lithium 65–6
- delirium, causes 5
- dementia
  - AD cause 185
  - causes 5
  - and cognitive impairment 168–77
  - DHEA and DHEA-S 152
  - food intake 10
  - risk from estrogen replacement therapy (ERT) 172–3
  - see also* Alzheimer's disease
- depression 60–3, 84–106, 114–36
  - causes 5
  - DHEA administration 154–5
  - epidemiology 84–5
  - estrogen deficiency 84–106
    - clinical/basic scientific evidence 95–7
    - hypothesis 85–6
  - and HPA axis 9–10
  - and HPT axis 60–3
    - antidepressants 64–6
  - levels of DHEA and DHEA-S 148–9
  - male 114–36
    - observational studies, HPG axis 127–30
    - testosterone in aging men 125–30
  - serotonergic antidepressant response 97–9
  - serotonin (5-HT) receptors 95–6
  - and thyroid hormones 60–3
    - summary 62–3
  - treatment
    - estrogen replacement therapy (ERT) 105–6
    - sleep deprivation 65
    - T<sub>3</sub> and imipramine 63–4
    - TRH test 61–2
      - see also* testosterone in male depression
- desipramine, menstrual cycle 326
- 20,22-desmolase 15
- dexamethasone/CRF test 43–4
- diabetes mellitus, cause of mental illness 4
- diagonal band of Broca (DBB), loss of cholinergic neurons in AD 185
- dihydrotestosterone (DHA) 16
- dimethylsulfoxide (DMSO) 147
- dopamine
  - estrogen effects 204, 253–4
  - estrogen-mediated release, nucleus accumbens 25
  - interactions with estrogens in schizophrenia 234–5
  - metabolism, tyrosine carboxylase 253
- dopamine receptor agonists, mimicking of progesterone 24
- dopamine receptor antagonists, and estrogen(s), tumor production 326
- drug pharmacokinetics 334–46
  - hormonal effects 334–46
- electromagnetic brain stimulation (EBS) 9
- endocrine disorders
  - behavioral effects 5
  - cause of mental illness 4–5
- endorphins, stress-induced analgesia 276–80
- epinephrine, postreceptor defects 7
- estradiol
  - metabolite of testosterone 117
  - and monamine oxidase activity 169
  - neuroprotective/neurotrophic effects 209
  - and stress responses 293–4
  - tissue-specific actions 104
- estrogen(s)
  - Alzheimer's disease 7–8
  - $\beta$ -amyloid processing 207
  - and basal forebrain cholinergic neurons 183–211
    - acetylcholine release 189–90
    - normal regulation 187–9
    - summary 203
  - brain aging and dementia in women 183–222
  - and cognitive function 7–8, 169–72
  - depression in aging women 84–113
    - epidemiology 84
    - serotonergic antidepressant response 97–9
  - effects on
    - adrenergic receptors 253
    - antibody production 290
    - apolipoprotein E 174
    - benzodiazepines 204–6
    - brain-derived neurotrophic factor 198–200
    - cholesterol, HDL and LDL 169
    - choline acetyltransferase 186–9

354 Index

- estrogen(s) (*cont.*)
  - coronary arteries 100, 103–4
  - dendritic spines 24
  - dopamine 204, 234–5, 253–4
  - GABA 204, 254
  - glutamate 204
  - glutamic acid decarboxylase 204
  - growth factors 194–200
  - hippocampal connectivity 206–7
  - immune function 290–6
  - learning and memory 184–5, 190–4
  - lorazepam 204–5
  - loss of ovarian function 200–3
  - monoamine oxidase 100, 169, 252–3
  - nerve growth factor 194–200
  - neuroprotection 87, 208–9
  - neurotransmitters 94–100, 204–6, 252–4
  - neurotrophin 198
  - nitric oxide release 100
  - norepinephrine 99–100, 204, 253
  - peripheral target tissues 103–4
  - rheumatoid arthritis 306
  - serotonin 94–9, 204
- genomic and non-genomic actions 102
- interactions with other hormones 100–2
- mediation by serotonin 94–9
- mediation of mood effects by neurotransmitters 94–100
- metabolism 102–3
- neurotransmission 252–4
- physiology and biochemistry 102–3
- plasma binding 17
- selective estrogen receptor modulators (SERMs) 92–3, 104, 174
- selective receptor modulators 174
- and symptoms of menopause 103
- therapy for mood disorders 87–9
- tissue-specific actions 104
- see also* estrogen replacement therapy
- estrogen receptors
  - cognitive effects 168–9
  - sexual dimorphism 25
  - sites 308
  - subtypes 21–2, 289–90
  - see also* selective estrogen receptor modulators (SERMs)
- estrogen replacement therapy (ERT)
  - and acetylcholine release 189–90
  - Alzheimer's disease 173–4
  - compliance 105–6
  - cytokine levels 291
  - deficiency hypothesis 85–6
  - dementia risk 172–3
  - early use 89
  - evidence for protection 86–7
  - interactions, progestin 100–1
  - learning and memory 190–4
  - meta-analysis 101
  - nitric oxide effects 100
  - norepinephrine effects 99–100
  - progesterin, mood effects 100–1
  - regimens 104–6
  - risks and benefits 105
  - in schizophrenia 253
  - stress-related changes in immune function 295–6
  - systemic effects 102–6
    - peripheral tissues 103–4
  - systemic lupus erythematosus risk 292
  - tissue-specific actions 104
  - trials 89–92
  - Women's Health Initiative Randomized Trial 176
- estrogen responsive elements (EREs) 309
- estrone, tissue-specific actions 104
- estrous cycle
  - basal forebrain cholinergic neurons, normal regulation 187–9
  - and ChAT 187–9
  - estrogen effects, BDNF and NGF 200
- ethinyl estradiol, tissue-specific actions 104
- euthyroid sick syndrome (ESS) 60
- fluoxetine, and ERT 98
- fluphenzine 328
- fluspirilene 328
- fluvoxamine 327
- follicle stimulating hormone (FSH) 16
- food intake, disturbances of aging 10
- Fos–Jun ratios 310
- GABA
  - estrogen effects 204, 254
  - and medroxyprogesterone acetate (MPA) 340–1
- GABA–steroid interactions 25
- GABA-active drugs, progesterone effects 334–46
- GABA<sub>A</sub> receptor complex 339
- gemfibrozil 325
- gender differences
  - Alzheimer's disease 322
  - anxiety disorders 243–52
  - autoimmune diseases 306
  - cognitive function 123–4
  - immune function 302–12
  - migraine headache 271, 273
  - neuroendocrine stress response 303–4
  - pain and pain inhibition 271–2
  - psychotropic drug metabolism 321–8
  - responses to analgesia 272–3
  - schizophrenia 223–35, 326
  - stress-induced analgesia 277–80
    - NMDA receptors 279–80

355 Index

- generalized anxiety disorder (GAD) 243–4
  - see also* anxiety disorders
- glucocorticoid receptors
  - hippocampal formation 21
  - stress-related genes 303–4
  - subtypes 21
- glucocorticoid responsive elements (GREs) 304–5
- glucocorticoids
  - age-associated changes 42–4
  - antagonism of estrogen receptors 25
  - functions 38
  - HPA axis 37–9
  - immune function regulation 304–5
  - interactions with estrogens 25–6
  - neuroendocrine stress response, gender differences 303–4
- glutamate, estrogen effects 204
- glutamic acid decarboxylase, estrogen effects 204
- gonadotropin-releasing hormone (GnRH) 116
- Graves' disease 58
- growth factors, and growth factor receptors, estrogen effects 194–200
- growth hormone 6
- haloperidol, and estrogen(s) 326
- headache, migraine, sex differences, 271, 273
- hepatic enzymes *see* cytochromes
- hippocampal formation
  - connectivity of basal forebrain cholinergic neurons 206–7
  - estrogen effects, 169, 206–7
    - brain-derived neurotrophic factor (BDNF) increase 198–9
  - estrogen effects on dendritic spines 24
  - glucocorticoid receptors 21
    - decline in aging rats 39–40
  - loss of cholinergic neurons in AD 185
  - and memory 44
  - paroxetine, PET radioligand 96
  - volume in Cushing's syndrome 44
- histidyl proline, TRH metabolites 56–7
- hormone replacement *see* estrogen replacement therapy (ERT)
- hormone response elements (HREs) 20
- hormones
  - and aging process 5–7
    - decrease/increase/no change 6
  - as basis of geriatric psychiatry 3–13
  - effect on drug pharmacokinetics 334–46
  - factors in pain and pain inhibition 273–4
  - interactions, and behavior 11
  - see also* named hormones
- hypergonadism
  - clinical studies 126–7
  - depression 126–7
- hyperthyroidism, depression 59–60
- hypogonadism 115
- hypothalamic–pituitary–adrenal (HPA) axis 37–45
  - ACTH action 16, 37–8, 292
  - activation and analgesia 278
  - aging 39–41
  - animal models 39–41
    - genetic vs. environmental influences 40
  - circadian rhythms 39
  - depression 9–10
  - disease states 43–4
  - glucocorticoids vs. estrogens 25–6
  - human studies 41–3
  - hypopituitarism 4
  - physiology 37–9
  - role in mood disorders 101
  - ventromedial, estrogen effects on dendritic spines 24
- hypothalamic–pituitary–gonadal (HPG) axis 16–18
  - physiology, male 116–24
  - role in mood disorders 101
  - testosterone, depression and aging 127–30
- hypothalamic–pituitary–hepatic (HPH) axis 323
- hypothalamic–pituitary–thyroid (HPT) axis 53–68
  - affective disorders 63–6
  - brain effects of TRH and metabolites 56–7
  - cognitive effects 66–7
  - and depression 60–3
  - elderly people 57–8
  - euthyroid sick syndrome (ESS) 60
  - hyperthyroidism 59–60
  - hypothyroidism 58–9
  - mood disorders in the elderly 58–63
  - physiology and regulation 54–6
- hypothyroidism 58–9
  - and cognition 66–7
  - treatment of depression 66
- imipramine
  - protein binding 323
  - serotonergic receptor binding 95–6
  - and T3, treatment for depression 63–4
- immobilization stress, BDNF 40
- immune function
  - effects of estrogen(s) 290–6
  - gender differences 302–12
- immune stressors, and HPA axis 39
- interleukins, induction by sex steroids 307–8
- ischemic injury, neuroprotective/neurotrophic effects of estrogen(s) 208–9
- learning, estrogen replacement therapy (ERT) 190–4
- leptin 10
- Leydig cells 16, 116, 118

356 Index

- lithium
  - antithyroid effects 65
  - and deiodinases 65–6
  - osteoporosis 327
- locus coeruleus, norepinephrine transporter (NET) 99
- lorazepam, estrogen effects 204–5
- luteinizing hormone (LH) 16, 116
- lymphokines, estrogen(s) 309
- male depression
  - role of testosterone 114–36
  - see also* testosterone in male depression
- Massachusetts Male Aging Study (MMAS) 126–7
- medial septum (MS)
  - ChAT production and estrogen 186–9
  - ChAT-like immunoreactive cells 188
  - estrous cycle and ChAT 187–9
  - loss of cholinergic neurons in AD 185
  - loss of ovarian function, effects on ChAT and Trk mRNA 202
  - TrkA cell surface receptor 195–200
  - TrkA mRNA, aging effects 201
- medroxyprogesterone, mood effects 101
- medroxyprogesterone acetate (MPA) 340–1
- melatonin 6, 65
- memory
  - BSRT 153
  - DHEA administration 156–8
  - estrogen replacement therapy (ERT) 190–4
  - hippocampal function 44
  - and role of basal forebrain cholinergic neurons 184–5
- menopause
  - anxiety disorders 256–7
  - and depression 103
  - mood disorders 256–7
  - surgical, PHA-induced GM–CSF 291
  - symptoms, and estrogens 103
  - see also* estrogen replacement therapy
- menstrual cycle
  - antipyrene elimination 326
  - progesterone, and benzodiazepine binding 344–5
  - SAM axis 292–4
- mental illness, hormonal causes 4–5
- mephenytoin hydroxylase (P450 C19) 324
- mesterolone, trials 134
- methylscopolamine, and memory dysfunction 184–5
- metyrapone, cortisol synthesis inhibition 42
- monoamine oxidase
  - activity, and estradiol 169
  - and estrogen(s) 100
  - estrogen effects 252–3
- mood disorders
  - DHEA administration 155–6
  - HPA and HPG axes 101–2
  - levels of DHEA and DHEA-S 148–9
  - mediation of effects by estrogen(s) 94–100
  - menopause 256–7
  - progesterin in ERT 100–1
  - raloxifene 94
  - therapy 87–9
  - and thyroid hormones 58–63
    - euthyroid sick syndrome (ESS) 60
    - hyperthyroidism 59–60
    - hypothyroidism 58–9
  - see also* depression
- multiple sclerosis, DHEA administration 154
- muscarinic receptor agonists, attenuation of memory deficits 185
- nefazodone 324, 327
- nerve growth factor (NGF), estrogen effects 194–200
- neuroendocrine stress response, gender differences 303–4
- neuronal growth, potential of DHEA and DHEA-S 148
- neuroprotective role of estrogen(s) 87
- neurosteroids 18
  - GABA receptor complex 339–40
  - see also* pregnenolone; progesterone
- neurotransmission
  - and sex steroids 252–5
  - estrogen(s) 252–4
  - progesterone 254–5
- neurotransmitters
  - biological effects of steroids 23–4
  - estrogen effects 204–6
  - HPT axis 60
  - hypothalamic 10
  - mediation of mood effects by estrogen(s) 94–100
- neurotrophin, estrogen effects 198
- NF–ATp, transcription factor 305
- nitric oxide, and estrogen 100
- NMDA receptors
  - estrogen-mediated modulation 25
  - and stress-induced analgesia, sex differences 279–80
  - synaptic input, mediation by estrogens 24
- norepinephrine
  - estrogen effects 99–100, 204, 253
  - postreceptor defects 7
- norepinephrine transporter (NET) 99
- nucleus basalis magnocellularis (NBM)
  - ChAT production and estrogen 186–9
  - loss of cholinergic neurons in AD 185
  - loss of ovarian function, effects on ChAT and Trk mRNA 202
  - TrkA cell surface receptor 195–200

Cambridge University Press

0521653045 - Hormones, Gender and the Aging Brain: The Endocrine Basis of Geriatric Psychiatry

Edited by Mary F. Morrison

Index

[More information](#)**357****Index**

- obsessive–compulsive disorder (OCD) 249–50
  - see also* anxiety disorders
- opiates, *kappa*-analgesia 279–80
- opioids, stress-induced analgesia 276–80
- oral contraceptives (OCs), benzodiazepine
  - metabolism 254–5, 326, 337–9
- ovarian function
  - cholinergic parameter changes 200–3
  - loss, effects on ChAT and Trk mRNA in MS and NBM 202
- ovulatory cycle, pain sensitivity in rodents 275
- oxytocin receptors, estrogen-mediated modulation 25
- P75<sub>NTR</sub> cell surface receptor, NGF mediation 194–200
- pain and pain inhibition 267–80
  - animal models 275–80
  - ovulatory cycle 275
  - hormonal factors 273–4
  - self-report, sociocultural influences 270
  - sex differences
    - health care utilization and chronic pain conditions 271–2
    - response to noxious stimuli 268–70
    - responses to analgesics 272–3
    - stress-induced analgesia 276–80
- panic disorder 244–6
- paroxetine, 5-HT transporter radioligand 96
- phobias
  - simple phobia 246–7
  - social phobia 247–9
  - see also* anxiety disorders
- pituitary *see* hypothalamic–pituitary–adrenal (HPA) axis
- positron emission tomography (PET)
  - anxiety disorder patients 252
  - serotonin radioligands 98
- post-traumatic stress disorder (PTSD) 250–2
  - see also* anxiety disorders
- pregnancy, anticonvulsants 327
- pregnenolone
  - action 6
  - allopregnenolone 340
  - benzodiazepine binding 341
  - influence of aging 345–6
  - cholesterol as source for synthesis 6, 15, 17
  - as neurosteroid 18
- progesterone
  - and benzodiazepine binding 341–6
  - CPT scores 342
  - exogenous administration 341–3
  - IM, mood effects 101
  - influence on GABA-active drugs 334–46
  - as neurosteroid 18
  - and neurotransmission 254–5
  - progesterin, mood effects 100–1
  - progesterin receptors 22
    - agonists, action 24
    - HRE binding 26
  - psychoneuroimmunology in women 289–96
  - psychotropic drug metabolism
    - gender differences 321–8
    - non-metabolic factors 322–3
  - psychotropic drugs, cardiovascular disease 322
  - raloxifene, ERT 94
  - receptor proteins 19–23
    - CNS localization and subtypes 21–3
  - 5- $\alpha$ -reductase 23
  - rheumatoid arthritis, estrogen effects 306
  - St Louis University study, androgen deficiency 9
  - schizophrenia 223–35
    - age of onset 223–4, 227
    - clinical studies of gender differences in neuropsychological variables 229–35, 326
    - clinical evaluation 230
    - comparison scales 232–3
    - materials and methods 229–30
    - neuropsychological tests 230–1
    - results and statistical methods 231
    - summary and discussion 231–5
  - cognitive performance 226–7
  - course of illness 225
  - dopamine–estrogen(s) interactions 234–5
  - neuroradiological abnormalities 227–8
  - symptom presentation 224–5
  - treatment
    - response to antipsychotics 228
    - tardive dyskinesia prevalence 228–9
- scopolamine, and memory dysfunction 184–5
- scopolamine amnesia 147
- selective estrogen receptor modulators (SERMs) 92–3, 104, 174
- senescent cells, sdi-1 gene 310
- serotonergic antidepressant response 97–9
- serotonin
  - effects in vitro 40
  - estrogen effects 204
  - estrogen mediation, evidence 95–7
  - mediation by estrogen 94–9
  - menstrual cycle 326
  - radioligands for PET, imaging data 98–9
  - synthesis, and gender, imaging data 98–9
- serotonin receptors
  - 5-HT<sub>1A</sub> 95
  - 5-HT<sub>2A</sub>, and depression 95–6
- serotonin transporter, depression in aging women 96–7

**358**      **Index**

- serotonin-specific reuptake inhibitors (SSRIs)
  - antidepressant response 97–9
  - and ERT 98
- sertraline, SSRI response 97–8
- sex hormone-binding globulin 116–17
- sex steroids
  - and anxiety disorders 241–57
  - female reproductive cycles 256–7
  - cognition and dementia, biological mechanisms 168–9
  - direct effects on immune function 309
  - induction of cellular events 307–8
  - and neurotransmission 252–5
  - regulation of immune function 306
  - see also named hormones*
- sleep deprivation, treatment for depression 65
- social phobia 247–9
- steroids 15–27
  - biological effects 23–4
  - interactions, other steroids 25–6
  - neurosteroids 18
  - novel effects 24–5
  - plasma binding 17
  - receptors 19–23
  - serum transport 15–19
  - sexual dimorphisms 25
  - synthesis 15–18
  - thyroid hormones 19
- stress response, neuroendocrine, gender differences 303–4
- stress-induced analgesia 276–80
  - aging effects 278
  - gender differences 277–80
- stress-related genes, glucocorticoid receptors 303–4
- stressors, estrogen-related differences in responses 292–4
- sympathetic–adrenal–medullary (SAM) axis 292–4
- systemic lupus erythematosus
  - DHEA administration 154
  - DHEA levels in females 306
  - and ERT 292
- tamoxifen
  - ERT 93–4
  - mood disorders 93–4
- tardive dyskinesia, prevalence in treated schizophrenia patients 228–9
- testosterone 114–43
  - actions 119–24
    - aggression 122–3
    - cognition 123–4
    - dominance and submission 121–2
    - exogenous treatment 130–6
    - metabolic effects 119
    - neuropsychiatric effects 119–24
    - perinatal organizing effects 119–20
    - postpubertal behavioral effects 8–9, 120–24
    - sexual behavior 122
  - administration
    - depressed men 133–5
    - depressed SSRI-refractive men 135
    - exogenous 130–1, 135–6
    - HIV-positive men 135
    - hypogonadal men 126–7
    - methodology 115–16, 131–5
    - non-depressed eugonadal men 131–2
    - non-depressed hypogonadal men 133
    - treatment method 135–6
  - in aging men 124–36
    - depressive illness 114–36
  - dihydrotestosterone (DHT) 16
  - half-life 116
  - HPG axis 127–30
  - mediation by estrogen receptors 23
  - metabolites 117
  - modulation of cognitive performance 174–6
  - physiology 116–24
  - replacement, trials 125, 130–5
  - secretion 116–18
    - and emotion 117–18
    - levels throughout life 118
  - synthesis 16–17
- testosterone binding globulin (TeBG) 17
- tetrahydrocorticosterone (THDOC) 339
- thiothixine 328
- thyroid hormone receptors 19–23
  - binding, stoichiometry 20
  - subtypes 23
- thyroid hormones
  - action 54–5
  - and aging 57–8
  - and c-erb 101
  - deiodinases 54
  - hypothyroidism 58–9
  - mood disorders 58–63
  - regulation 55–6
  - synthesis and release 19
  - see also* hypothalamic–pituitary–thyroid (HPT) axis
- thyrotrophin-releasing hormone (TRH) 54–6
  - and antidepressants 64–6
  - immunoreactive cell bodies 56
  - metabolites 56–7
  - TRH test in depression 61–2
- transcortin, cortisol binding 17
- transcription factors
  - DNA binding 311
  - SP-1 311
- trazodone 327
  - antipyrene elimination 326



**359**      **Index**

tri-iodothyronine (T3)	vasopressin
deiodinases 65–6	CRF cells 43
with imipramine, treatment for depression	levels 7
63–4	role in aging 41
triazolam 324, 341–2	Veterans' Experience Study (VES) 126–7
TrkA cell surface receptor, NGF mediation	vitamin D, levels 7
194–200	
tyrosine, synthesis of thyroid hormone 19	women
tyrosine carboxylase, dopamine metabolism 253	life expectancy, US 103
tyrosine kinase, TrkA cell surface receptor, NGF	psychoneuroimmunology 289–96
mediation 194–200	Women's Health Initiative Randomized Trial 176